Anti-inflammatory agent 35

• CAT Number: I041774
• CAS Number: 2293951-00-3
• Molecular Formula: C27H29NO8
• Molecular Weight: 495.52
• Purity: ≥95%
• Synonyms: [2-methoxy-4-[(E)-3-oxo-3-[(3E)-2-oxo-3-[(3,4,5-trimethoxyphenyl)methylidene]piperidin-1-yl]prop-1-enyl]phenyl] acetate
• InChI: InChI=1S/C27H29NO8/c1-17(29)36-21-10-8-18(14-22(21)32-2)9-11-25(30)28-12-6-7-20(27(28)31)13-19-15-23(33-3)26(35-5)24(16-19)34-4/h8-11,13-16H,6-7,12H2,1-5H3/b11-9+,20-13+
• InChIKey: QLGWATTXCFBRGY-ZEQSIELKSA-N
• SMILES: CC(=O)OC1=C(C=C(C=C1)C=CC(=O)N2CCCC(=CC3=CC(=C(C(=C3)OC)OC)OC)C2=O)OC

Anti-inflammatory agent 35 (compound 5a27) is an orally active curcumin analogue with anti-inflammatory activity. Anti-inflammatory agent 35 blocks mitogen-activated protein kinase (MAPK) signaling and p65 nuclear translocation of NF-kB. Anti-inflammatory agent 35 also inhibits yellow neutrophil infiltration and pro-inflammatory cytokine production. Anti-inflammatory agent 35 significantly attenuates lipopolysaccharide (LPS)-induced acute lung injury (ALI) in vivo[1].
Anti-inflammatory agent 35 (compound 5a27) (10 μM; 30 min) inhibits the production of proinflammatory cytokines (IL-6, TNF-α) induced by LPS (0.5 μg/mL; 24 h) without cytotoxicity in mouse primary macrophages (MPMs). Anti-inflammatory agent 35 inhibits the production of IL-6, TNF-α with IC50s of 2.23 μM and 2.40 μM, respectively[1].
Anti-inflammatory agent 35 (10 μM; 30 min) significantly inhibits LPS-induced activation in RAW 264.7 mouse macrophages. And it markedly inhibits p-p38 and p-ERK, decreases IκB level, indicating the suppression of MAPK and NF-κB signaling[1].
Anti-inflammatory agent 35 (compound 5a27) (50 mg/kg; po; single dose, monitored 0-25 min) has a better bioavailability than curcumin (HY-N0005)[1].
Anti-inflammatory agent 35 (10 mg/kg; ip; once daily for 1 week) improves LPS-induced ALI by inhibiting inflammation in mice model[1].
The pharmacokinetic parameters in rats[1]

Route
Dose (mg/kg)
AUC(0-t) (μg/L·h)
AUC(0-∞) (μg/L·h)
MRT(0-t) (h)
MRT(0-∞) (h)
t1/2 (h)
Tmax (h)
CLz/F (L/h/kg)
Vz/F (L/kg)
Cmax

p.o
50
231.2
325.6
7.8
12.3
6.7
3.3
5062.6
827.1
113.3

i.v
5
34.3
122.4
11.3
19.9
0.2
0.1
404.4
59.5
16.4

Reference

[1]. Qian J, et al. Design and synthesis novel di-carbonyl analogs of curcumin (DACs) act as potent anti-inflammatory agents against LPS-induced acute lung injury (ALI). Eur J Med Chem. 2019 Apr 1;167:414-425.
 [Content Brief]